The industrial side of the peptide category — capacity, chemistry, cost of goods, and the decisions that sit behind them. Written for the people who have to make these molecules, not only the ones who discovered them.
Cadence
Roughly monthly
Written by
CDMO Hub
Archive
5 issues
New briefings land in your inbox, with the designed PDF. Roughly monthly.
Peptide-based oncology programs use comparatively little API, but their manufacturing needs are exacting: small-scale GMP availability, specification control, analytical capability, inspection readiness, and a supply chain aligned to the patient.
Oncology peptides · scale and scheduling
Small API mass shifts the capacity question from reactor volume toward specifications, suite availability, release timing, and supply-chain reliability.
01
Who actually has GMP peptide capacity, when it is contracted to, and what "available" means on a 2029 timeline.
02
Solid-phase and hybrid synthesis, sequence complexity, impurity profiles, and the analytical depth to characterise them.
03
How yield and fill-finish throughput flow into price, and how price determines access.
04
What sponsors weigh at partner selection, and what gets discovered too late at tech transfer.
Most peptide CDMO selection frameworks were written when capacity was available. They ask reasonable questions at the wrong level of specificity — and where qualified commercial capacity is scarce, that imprecision costs a place in the queue. Six recurring failure modes, and the evidence that settles each one.
Solid-phase peptide synthesis consumes around 13,000 kg of material for every kg of API — forty to eighty times a small molecule. As GLP-1-class demand pushes volumes the industry has never operated at, solvent supply, recovery, and disposal are becoming the binding constraint.
We tracked more than twenty peptide facility announcements from 2024 to 2026. Only a handful add commercial-scale API capacity — and in 2026, consolidation quietly shrank the field rather than widening it.
Two Phase 3 readouts have reset the ceiling for what peptide therapeutics can do. The more interesting story is everything the efficacy headline leaves out.